Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Biogen Q3 2026 Results: Net Loss of $20.6M

Biogen Inc. filed its Q3 2026 10-Q reporting on the quarterly period ended September 30, 2026. The filing highlights the company's strategic focus on product launches like LEQEMBI and SKYCLARYS, as well as the integration of acquisitions such as Reata, HI-Bio, and Apellis.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue2,804.12,534.7
Profit before tax-9.0557.3
Net income-20.6466.5
EPS (diluted, $ a share)$-0.14$3.17

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year+10.6%
Source

10-Q filed with the SEC, NASDAQ: BIIB. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Biogen Inc.: key numbers

Share price
$251.65Close, Nov 16
Market cap
$37.2B
Shares outstanding
147.82MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Biogen Inc.

All →
6:08 AM ET 8-K
Financial Results

Biogen Financial Results

Biogen reported third quarter 2026 total revenue of $2.8 billion, an 11% increase year-over-year, driven by a 49% surge in its Growth Portfolio which now represents 63% of core pharmaceutical revenue. The results include the first full quarter of contribution from the acquired Apellis products and strong performance from SPINRAZA and LEQEMBI.

Term
Q3 2026

“Our third quarter results demonstrate that Biogen has returned to growth. We’re seeing the strength of our Growth Portfolio – including the first full quarter of results from Apellis products – which helped drive double-digit revenue growth and an approximately 50% year-over-year increase from our growth products.”

Christopher A. Viehbacher, President and Chief Executive Officer

“With multiple Phase 3 readouts expected over the next 12 months, we are positioned to further strengthen our long-term growth profile and create sustainable value for patients and shareholders.”

Christopher A. Viehbacher, President and Chief Executive Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.